TOP
Nav Bar
  1. General Info
  2. Effects Info
  3. Reference
Drug Details
01. General Information
Name Imatinib
PubChem CID 123596
Molecular Weight 589.7g/mol
Synonyms

Imatinib mesylate, 220127-57-1, Gleevec, Glivec, Imatinib mesilate, imatinib methanesulfonate, Imatinib Mesylate (STI571), sti-571, Imatinib accord, Imatinib medac, Imatinib (mesylate), imatinib monomesylate, Shantinib, Imatinib (as mesilate), NSC-716051, QTI-571, Imatinib methane sulfonate, CGP 57148B, Gleevec (Imatinib mesylate), QTI571, STI 571, 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide monomethanesulfonate, DTXSID9040502, CHEBI:31690, HSDB 7142, Imatinib Methansulfonate, 8A1O1M485B, 220127-57-1 (mesylate), Imatinib mesylate [USAN], Imatinib monomethanesulfonate, UNII-8A1O1M485B, N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide methanesulfonate, DTXCID7020502, MFCD04307699, NSC716051, NSC 716051, N-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide methanesulfonate, Imatinib mesilate (JAN), Imatinib mesylate (USAN), 4-[(4-methyl-1-piperazinyl)methyl]-n-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide methanesulfonate, Benzamide, 4-((4-methyl-1-piperazinyl)methyl)-N-(4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)phenyl)-, monomethanesulfonate, Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (1:1), IMATINIB MESILATE [JAN], IMATINIB MESILATE (MART.), IMATINIB MESILATE [MART.], CGP-57148B, IMATINIB MESILATE (EP MONOGRAPH), IMATINIB MESILATE [EP MONOGRAPH], CAS-220127-57-1, CGP-57148, NCGC00159456-02, Genfatinib, Gleevac, ImatinibMesylate, Imatinib, methanesulfonate salt, Imatinib mesylate?, Mesylate, Imatinib, 4-((4-methylpiperazin-1-yl)methyl)-N-(4-methyl-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)phenyl)benzamide methanesulfonate, 4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide methanesulfonate, 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate, 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate, 4-[(4-methylpiperazin-1-yl)methyl]-N-{4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl}benzamide methanesulfonate, Gleevec (TN), Glivec (TN), ST-1571 Mesylate, Imatinib mesylate400 mg, Methanesulfonate, Imatinib, SCHEMBL8217, CHEMBL1642, Benzamide,monomethanesulfonate, Imatinib methanesulfonate salt, MLS001401456, C29H31N7O.CH4O3S, IMATINIB MESYLATE [HSDB], CGP57148B, EX-A954, IMATINIB MESYLATE [VANDF], YLMAHDNUQAMNNX-UHFFFAOYSA-N, BCPP000204, GGP-57148B, HMS2052B09, HMS2233D16, HMS3265E01, HMS3265E02, HMS3265F01, HMS3265F02, HMS3372O12, HMS3394B09, HMS3654C07, IMATINIB MESILATE [WHO-DD], BCP01255, Tox21_111684, AC-525, HB1943, s1026, IMATINIB METHANESULFONATE [MI], AKOS015852497, Tox21_111684_1, BCP9000776, CCG-101175, IMATINIB MESYLATE [ORANGE BOOK], KS-1236, NC00425, NCGC00159456-11, 111GE005, BI164678, HY-50946, methanesulfonic acid; 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide, SMR000469175, SY013513, AM20080900, FT-0601612, I0936, NS00076459, SW197805-4, D01441, Imatinib Mesylate (CGP-57148B, STI-571), M06311, A815828, A846640, J-523068, Q-201232, Q27114666, Imatinib Mesylate,Gleevec,Glivec,CGP-57148B,STI-571, ST-1571 Mesylate , STI-571 , CGP-57148B, ;4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate, 4-((4-Methyl-1-piperazinyl)methyl)-N-(4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)phenyl)benzamide Monomethanesulfonate, 4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin- 3-yl)-pyrimidin-2-ylamino)-phenyl]-benzamidemethanesulfonic acid salt, 4-(4-Methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)phenyl]benzamide methanesulfonic acid salt, 4-[(4-Methyl-1-piperazinyl)-methyl]-N-{4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]-amino]-phenyl}-benzamide monomethanesulphonate, 4-[(4-methyl-1-piperazinyl)methyl]-n-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide methanesulfonate, BENZAMIDE, 4-((4-METHYL-1-PIPERAZINYL)METHYL)-N-(4-METHYL-3-((4-(3-PYRIDINYL)-2-PYRIMIDINYL)AMINOPHENYL)-, METHANESULFONATE SALT, BENZAMIDE, 4-((4-METHYL-1-PIPERAZINYL)METHYL)-N-(4-METHYL-3-((4-(3-PYRIDINYL)-2-PYRIMIDINYL)AMINOPHENYL)-, METHANESULPHONATE SALT, hydron;methanesulfonate;4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide, methanesulfonic acid; 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide, N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamidemethanesulfonate
Drug Type Small molecule
Formula C₃₀H₃₅N₇O₄S
SMILES CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5.CS(=O)(=O)O
InChI 1S/C29H31N7O.CH4O3S/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36;1-5(2,3)4/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34);1H3,(H,2,3,4)
InChIKey YLMAHDNUQAMNNX-UHFFFAOYSA-N
CAS Number 220127-57-1
ChEMBL ID CHEMBL1642
ChEBI ID CHEBI:31690
TTD ID D0AZ3C
KEGG ID D01441
Toxicity Organism Test Type Route(Dose)
rat LD50 intraperitoneal(165 mg/kg)
mouse LD50 intraperitoneal(254 mg/kg)
rat LD50 oral(322 mg/kg)
Structure 2D-img
Download
2D MOL 3D MOL
02. Combinatorial Therapeutic Effect(s)
Synergistic Effect
Hide/Show
Enhancing Drug Efficacy
Hide/Show
Combination Pair ID: 572
Ref_1
Pair Name Vitamin K3, Imatinib
Partner Name Vitamin K3
Disease Info [ICD-11: 2B33.2] Chronic myeloid leukemia Investigative
Gene Regulation Down-regulation Expression ABCB1 hsa5243
In Vitro Model K-562 Blast phase chronic myelogenous leukemia Homo sapiens (Human) CVCL_0004
Result The results demonstrate that menadione and imatinib combination therapy may be a promising approach to refractory CML.
Combination Pair ID: 747
Ref_2
Pair Name Thymoquinone, Imatinib
Partner Name Thymoquinone
Disease Info [ICD-11: 2B90] Colon cancer Investigative
Biological Phenomena Induction-->Cell uptake or efflux
Gene Regulation Down-regulation Expression ABCB1 hsa5243
Down-regulation Expression ABCG2 hsa9429
Down-regulation Expression SLC22A1 hsa6580
In Vitro Model HCT 116 Colon carcinoma Homo sapiens (Human) CVCL_0291
Result TQ potentiates IM efficacy on HCT116 cells via uptake/efflux genes modulation
Combination Pair ID: 295
Ref_3
Pair Name Tanshinone IIA, Imatinib
Partner Name Tanshinone IIA
Disease Info [ICD-11: 2A20.1] Chronic myelogenous leukemia Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Down-regulation Phosphorylation AKT1 hsa207
Down-regulation Cleavage CASP3 hsa836
Down-regulation Expression MKI67 hsa4288
Down-regulation Expression MMP9 hsa4318
Down-regulation Phosphorylation MTOR hsa2475
Down-regulation Phosphorylation PIK3CA hsa5290
Down-regulation Expression VEGFA hsa7422
In Vitro Model Jurkat Childhood T acute lymphoblastic leukemia Homo sapiens (Human) CVCL_0065
In Vivo Model TBI-152 cells (4×10⁶) were injected into the right flank of the mice.
Result The results revealed that Tan IIA enhanced the inhibitory effect of imatinib on TIB‑152 cell proliferation, migration and invasion, and induced apoptosis, which may be associated with inhibition of the PI3K/AKT/mTOR signaling pathway.
Combination Pair ID: 676
Ref_4
Pair Name Oridonin, Imatinib
Partner Name Oridonin
Disease Info [ICD-11: 2B33.3] Acute lymphoblastic leukemia Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Down-regulation Expression AKT1 hsa207
Up-regulation Expression BAX hsa581
Up-regulation Expression BCL2 hsa596
Down-regulation Expression JTK8 hsa4067
Down-regulation Expression MEK1 hsa5604
Down-regulation Expression MTOR hsa2475
Down-regulation Expression RAF1 hsa5894
Down-regulation Expression STAT5B hsa6777
In Vitro Model SUP-B15 Childhood B acute lymphoblastic leukemia with t Homo sapiens (Human) CVCL_0103
Result Our data showed that oridonin remarkably suppressed activations of Akt/mTOR, Raf/MEK and STAT5 pathway in these primary specimens and oridonin with imatinib exerted synergetic suppressive effects on mTOR, STAT5 and LYN signaling in one imatinib resistant patient specimen. Additional evaluation of oridonin as a potential therapeutic agent for Ph+ ALL seems warranted.
Combination Pair ID: 851
Ref_5
Pair Name Luteolin, Imatinib
Partner Name Luteolin
Disease Info [ICD-11: 2A20.1] Chronic myelogenous leukemia Investigative
Biological Phenomena Induction-->Apoptosis
In Vitro Model K-562 Blast phase chronic myelogenous leukemia Homo sapiens (Human) CVCL_0004
Result The combination of some flavonoids and imatinib mesylate may increase the cytotoxic effect; However, the antagonistic effect should be considered in combined use on k562 cells.
Combination Pair ID: 874
Ref_6
Pair Name Gossypol, Imatinib
Partner Name Gossypol
Disease Info [ICD-11: 2B33.4] Leukemia Investigative
Biological Phenomena Induction-->Mitochondria-mediated apoptosis
Gene Regulation Down-regulation Expression BCL2 hsa596
Down-regulation Expression BCL-xL hsa598
Up-regulation Cleavage CASP3 hsa836
Down-regulation Expression MCL1 hsa4170
In Vitro Model K-562 Blast phase chronic myelogenous leukemia Homo sapiens (Human) CVCL_0004
Result These results suggest that (-)gossypol induced apoptosis in K562 cells through a mitochondria pathway and that the combination of imatinib and (-)gossypol might be an effective treatment for CML.
Combination Pair ID: 705
Ref_7
Pair Name Costunolide, Imatinib
Partner Name Costunolide
Disease Info [ICD-11: 2B33.3] Acute lymphoblastic leukemia Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Up-regulation Cleavage CASP3 hsa836
In Vitro Model K-562 Blast phase chronic myelogenous leukemia Homo sapiens (Human) CVCL_0004
Result These results demonstrate that costunolide may be a potent therapeutic agent against chronic myeloid leukemia.
Combination Pair ID: 213
Ref_8
Pair Name Betulinic acid, Imatinib
Partner Name Betulinic acid
Disease Info [ICD-11: 2B33.2] Chronic myeloid leukemia Investigative
Gene Regulation Up-regulation Expression ABL1 hsa25
Up-regulation Expression BAX hsa581
Down-regulation Expression BCL2 hsa596
Up-regulation Cleavage CASP3 hsa836
Up-regulation Cleavage CASP9 hsa842
Down-regulation Expression CDK1 hsa983
Up-regulation Acetylation H3C14 hsa126961
Up-regulation Acetylation H4C14 KEGG ID N.A.
Down-regulation Expression HDAC3 hsa8841
Up-regulation Cleavage PARP1 hsa142
Down-regulation Phosphorylation RB1 hsa5925
In Vitro Model K-562R Blast phase chronic myelogenous leukemia Homo sapiens (Human) CVCL_5950
Result Our findings demonstrated that HDAC3 is an essential factor in BCR-ABL1 kinase-independent IM resistance, and that BA in combination with IM may be a novel treatment strategy for overcoming IM resistance in CML.
Combination Pair ID: 516
Ref_9
Pair Name All-trans retinoic acid, Imatinib
Partner Name All-trans-retinoic acid
Disease Info [ICD-11: 2A60.Z] Acute myeloid leukemia Investigative
Gene Regulation Down-regulation Expression ABCB1 hsa5243
Down-regulation Expression ABL1 hsa25
In Vitro Model K-562 Blast phase chronic myelogenous leukemia Homo sapiens (Human) CVCL_0004
Result Combined ATRA and IM therapy was shown to be effective in decreasing BCR-ABL and ABCB1 genes, possibly through the differentiation of blast cells, demonstrating that the therapy could be potentially effective in the blast crisis of the disease and for those patients who develop resistance to available CML treatments.
Reversing Drug Resistance
Hide/Show
Combination Pair ID: 110
Ref_10
Pair Name Norizalpinin, Imatinib
Partner Name Norizalpinin
Disease Info [ICD-11: 2B33.4] Leukemia Investigative
Biological Phenomena Induction-->Blockade of cell cycle in G0/G1 phase
Gene Regulation Down-regulation Expression BCL2 hsa596
Down-regulation Expression CDK1 hsa983
Down-regulation Expression CDK4 hsa1019
Down-regulation Expression RB1 hsa5925
In Vitro Model K-562 Blast phase chronic myelogenous leukemia Homo sapiens (Human) CVCL_0004
KCL-22 Chronic myelogenous leukemia, BCR-ABL1 positive Homo sapiens (Human) CVCL_2091
Result Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells
03. Reference
No. Title Href
1 The potentiation of menadione on imatinib by downregulation of ABCB1 expression. Clin Exp Pharmacol Physiol. 2020 Jun;47(6):997-1004. doi: 10.1111/1440-1681.13293. Click
2 Thymoquinone chemosensitizes human colorectal cancer cells to imatinib via uptake/efflux genes modulation. Clin Exp Pharmacol Physiol. 2021 Jun;48(6):911-920. doi: 10.1111/1440-1681.13476. Click
3 Tanshinone IIA enhances the inhibitory effect of imatinib on proliferation and motility of acute leukemia cell line TIB‑152 in vivo and in vitro by inhibiting the PI3K/AKT/mTOR signaling pathway. Oncol Rep. 2020 Feb;43(2):503-515. doi: 10.3892/or.2019.7453. Click
4 Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway. Cancer Biol Ther. 2012 Nov;13(13):1244-54. doi: 10.4161/cbt.21460. Click
5 Cytotoxic Effects of Some Flavonoids and Imatinib on the K562 Chronic Myeloid Leukemia Cell Line: Data Analysis Using the Combination Index Method. Balkan Med J. 2019 Feb 28;36(2):96-105. doi: 10.4274/balkanmedj.galenos.2018.2017.1244. Click
6 (-)Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells. Leuk Lymphoma. 2007 Nov;48(11):2204-12. doi: 10.1080/10428190701583991. Click
7 Costunolide promotes imatinib-induced apoptosis in chronic myeloid leukemia cells via the Bcr/Abl-Stat5 pathway. Phytother Res. 2018 Sep;32(9):1764-1769. doi: 10.1002/ptr.6106. Click
8 Betulinic acid restores imatinib sensitivity in BCR-ABL1 kinase-independent, imatinib-resistant chronic myeloid leukemia by increasing HDAC3 ubiquitination and degradation. Ann N Y Acad Sci. 2020 May;1467(1):77-93. doi: 10.1111/nyas.14298. Click
9 Combined Therapy of ATRA and Imatinib Mesylate Decreases BCR-ABL and ABCB1/MDR1 Expression Through Cellular Differentiation in a Chronic Myeloid Leukemia Model. In Vivo. 2021 Sep-Oct;35(5):2661-2667. doi: 10.21873/invivo.12549. Click
10 Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells. Cancer Lett. 2008 Jul 8;265(2):289-97. doi: 10.1016/j.canlet.2008.02.025. Click
It has been 26311 visits since 2024.08
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang
TOP